Schizophrenia Research
Volume 73, Issue 2 , Pages 147-152 , 1 March 2005

Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartate and N-acetylaspartylglutamate in rat brain

  • Lindsay M. Reynolds

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44-114-222-2313; fax: +44-114-276-5413.
    • Department of Biomedical Science, University of Sheffield, Western Bank, Sheffield S10 2TN, UK
    • ,
  • Susan M. Cochran

      Affiliations

    • Yoshitomi Research Institute of Neuroscience in Glasgow, University of Glasgow, Glasgow G12 8QQ, UK
    • ,
  • Brian J. Morris

      Affiliations

    • Yoshitomi Research Institute of Neuroscience in Glasgow, University of Glasgow, Glasgow G12 8QQ, UK
    • ,
  • Judith A. Pratt

      Affiliations

    • Yoshitomi Research Institute of Neuroscience in Glasgow, University of Glasgow, Glasgow G12 8QQ, UK
    • ,
  • Gavin P. Reynolds

      Affiliations

    • Department of Biomedical Science, University of Sheffield, Western Bank, Sheffield S10 2TN, UK
    • Current address of Gavin P. Reynolds, Department of Mental Health, Queen's University Belfast, Whitla Medical Building, 97 Lisburn Road, Belfast, BT9 7BL.

Received 4 February 2004 ,Revised 4 February 2004 ,Accepted 4 February 2004.

References 

  1. Abdul-Monim Z, Neill JC, Reynolds GP. Sub-chronic PCP administration significantly alters parvalbumin-immunoreactive interneurones in the prefrontal cortex and hippocampus of the rat. Br. Neurosci. Assoc. Abstr. 2003;17:103
  2. Allen RM, Young SJ. Phencylidine-induced psychosis. Am. J. Psychiatry. 1978;135:1081–1084
  3. Anderson KJ, Monaghan DT, Cangro CB, Namboodiri MAA, Neale JH, Beasley CL, et al. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr. Res. 1997;24:349–355
  4. Beasley CL, Reynolds GP. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr. Res. 1997;24:349–355
  5. Bertolino A, Callicott JH, Elman I, Mattay VS, Tedeschi G, Frank JA, et al. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol. Psychiatry. 1998;43:641–648
  6. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF, et al. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol. Psychiatry. 2001;49:39–46
  7. Cecil KM, Lenkinski RE, Gur RE, Gur RC. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology. 1999;20:131–140
  8. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ. Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology. 2003;28:265–275
  9. Corso TD, Sesma MA, Tenkova TI, Der TC, Wozniak DF, Farber NB, et al. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res. 1997;752:1–14
  10. Crow TJ. Constraints on concepts of pathogenesis. Language and the speciation process as the key to the etiology of schizophrenia. Arch. Gen. Psychiatry. 1995;52:1011–1014
  11. Danos P, Baumann B, Bernstsin HG, Franz M, Stauch R, Northoff G, et al. Proton magnetic resonance spectroscopy of the human brain in schizophrenia. Rev. Neurosci. 2000;11:147–158
  12. Flores C, Coyle JT. Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencyclidine, haloperidol, and clozapine. Neuropsychopharmacology. 2003;28:1227–1234
  13. Forloni G, Grzanna R, Blakely RD, Coyle JT. Co-localization of N-acetyl-aspartyl-glutamate in central cholinergic, noradrenergic, and serotonergic neurons. Synapse. 1987;1:455–460
  14. Fukuzako H, Takeuchi K, Hokazono Y, Fukuzako T, Yamada K, Hashiguchi T, et al. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatry Res. 1995;61:193–200
  15. Grunze H, Rainnie D, Hearn E, Barkai E, Hasselmo M, McCarley R, et al. Impaired LTP of recurrent inhibition onto hippocampal pyramidal cells: a possible cellular basis of schizophrenia. Schizophr. Res. 1995;15:28–29
  16. Henn FA. The NMDA receptor as a site for psychopathology. Primary or secondary role?. Arch. Gen. Psychiatry. 1995;52:1008–1010
  17. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 1991;148:1301–1308
  18. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20:201–225
  19. Jentsch JD, Redmond DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 1997;277:953–955
  20. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology. 1997;17:92–99
  21. Luby ED, Cohen CB, Rosenbaum G, Gottlieb JS, Kelly R. Study of a new schizophrenomimetic drug—Serynl. Arch. Neurol. Psychiatry. 1959;81:363–369
  22. Neale JH, Bzdega T, Wroblewska B. N-acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J. Neurochem. 2000;75:443–452
  23. Nudmamud S, Reynolds LM, Reynolds GP. N-acetylaspartate and N-acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder. Biol. Psychiatry. 2003;53:1138–1141
  24. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244:1360–1362
  25. Olney JW, Farber NB, Nuri B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 1995;52:998–1007
  26. Omori M, Pearce J, Komoroski RA, Griffin WS, Mrak RE, Husain MM, et al. In vitro 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia. Biol. Psychiatry. 1997;42:359–366
  27. O'Neill J, Eberling JL, Schuff N, Jagust W, Reed B, Soto G, et al. Method to correlate 1H MRSI and 18FDG-PET. Magn. Reson. Med. 2000;43:244–250
  28. Passani LA, Vonsattel JP, Carter RE, Coyle JT. N-acetylaspartylglutamate, N-acetylaspartate, and N-acetylated alpha-linked acidic dipeptidase in human brain and their alterations in Huntington and Alzheimer's diseases. Mol. Chem. Neuropathol. 1997;31:97–118
  29. Passani LA, Vonsattel JP, Coyle JT. Distribution of N-acetylaspartylglutamate immunoreactivity in human brain and its alteration in neurodegenerative disease. Brain Res. 1997;772:9–22
  30. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press; 1998;
  31. Pearlson GD, Marsh L. Structural brain imaging in schizophrenia: a selective review. Biol. Psychiatry. 1999;46:627–649
  32. Rowland L, Bustillo JR, Lauriello J. Proton magnetic resonance spectroscopy (H-MRS) studies of schizophrenia. Semin. Clin. Neuropsychiatry. 2001;6:121–130
  33. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psychiatry. 1992;49:522–530
  34. Trombley PQ, Westbrook GL. Excitatory synaptic transmission in cultures of rat olfactory bulb. J. Neurophysiol. 1990;64:598–606
  35. Tsai G, Passani LA, Slusher BS, Carter R, Baer L, Kleinman JE, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry. 1995;52:829–836
  36. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, et al. Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiatry. 2001;50:825–844
  37. Westbrook GL, Mayer ML, Namboodiri MA, Neale JH. High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture. J. Neurosci. 1986;6:3385–3392
  38. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch. Gen. Psychiatry. 1992;49:959–965

PII: S0920-9964(04)00051-9

doi: 10.1016/j.schres.2004.02.003

Schizophrenia Research
Volume 73, Issue 2 , Pages 147-152 , 1 March 2005

Article Tools

* Image Usage & Resolution